文献速递肝病消化道肿瘤与早癌

HCV清除对接受射频消融的HCV相关肝细胞癌患者复发模式及长期结局的影响

Impact of HCV eradication on recurrence pattern and long-term outcomes in patients with HCV-related hepatocellular carcinoma undergoing radiofrequency ablation.
PubMed 文献 · Aliment Pharmacol Ther · 2024-08-07

该回顾性研究纳入274例接受射频消融的HCV相关肝细胞癌患者,其中73例接受干扰素治疗、88例接受直接抗病毒药物治疗。HCV清除与远处复发风险降低、总生存改善及肝功能失代偿减少显著相关,但与局部肿瘤进展无关。

要点

  • HCV清除与远处复发风险降低显著相关(DAA治疗HR=0.449,p=0.006)。
  • HCV清除与总生存改善显著相关(IFN治疗HR=0.242,p<0.001;DAA治疗HR=0.274,p<0.001)。
  • HCV清除与肝功能失代偿减少显著相关(IFN治疗HR=0.313,p=0.004;DAA治疗HR=0.281,p<0.001)。

核心结论

  • HCV清除与接受射频消融的HCV相关肝细胞癌患者远处复发、死亡及肝功能失代偿的显著减少相关。

研究设计与样本

  • 回顾性纳入274例接受射频消融治疗的HCV相关肝细胞癌患者,其中73例接受干扰素治疗、88例接受直接抗病毒药物治疗。

主要发现

  • 干扰素治疗组49.3%的患者获得持续病毒学应答,直接抗病毒药物治疗组93.2%的患者获得持续病毒学应答。
  • HCV清除与局部肿瘤进展无关,但与远处复发风险降低显著相关(DAA治疗HR=0.449,p=0.006)。
  • HCV清除与总生存改善显著相关(IFN治疗HR=0.242,p<0.001;DAA治疗HR=0.274,p<0.001)。
  • HCV清除与肝功能失代偿减少显著相关(IFN治疗HR=0.313,p=0.004;DAA治疗HR=0.281,p<0.001)。
  • 获得持续病毒学应答的患者FIB-4评分显著下降,且ALBI分级改善比例更高。

关键数值与推荐

  • 在持续病毒学应答患者中,IMbrave050标准可预测局部肿瘤进展,但不能预测远处复发。
  • 在持续病毒学应答患者中,预测远处复发的是持续病毒学应答后的FIB-4评分,而非基线FIB-4评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefits of HCV eradication on distinct recurrence patterns and long-term hepatic outcomes in patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA) remain uncertain. This study aims to assess the impact of HCV eradication on HCC recurrence patterns and long-term hepatic outcomes after RFA and to identify predictors of recurrence in patients achieving sustained virological response (SVR). METHODS: We retrospectively enrolled 274 patients receiving RFA for HCV-related HCC, including 73 and 88 patients treated with interferon-based (IFN) and direct-acting antivirals (DAA) therapy, respectively. We analysed factors associated with local tumour progression (LTP), distant recurrence, overall survival, and hepatic decompensation. RESULTS: SVR was achieved in 49.3% of patients undergoing IFN therapy and 93.2% of patients undergoing DAA therapy. HCV eradication was not associated with LTP but significantly correlated with reduced risk of distant recurrence (by DAA: hazard ratio (HR) = 0.449, p = 0.006), overall survival (by IFN: HR = 0.242, p < 0.001; by DAA: HR = 0.274, p < 0.001) and hepatic decompensation (by IFN: HR = 0.313, p = 0.004; by DAA: HR = 0.281, p < 0.001). The benefits of achieving SVR in terms of overall survival and hepatic decompensation remained significant in subgroups of patients with and without recurrence. Patients with SVR showed a significant decline in FIB-4 score and a higher proportion of ALBI grade improvement. Among SVR patients, the IMbrave050 criteria predicted LTP but not distant recurrence, whereas the FIB-4 score after SVR, rather than the baseline FIB-4, predicted distant recurrence. CONCLUSIONS: HCV eradication was associated with a significant reduction in distant recurrence, mortality and hepatic decompensation following RFA in patients with HCV-related HCC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wu KC, Lee IC, Chi CT, et al. Impact of HCV eradication on recurrence pattern and long-term outcomes in patients with HCV-related hepatocellular carcinoma undergoing radiofrequency ablation. Aliment Pharmacol Ther. 2024. PMID: 39113355. doi:10.1111/apt.18199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。